PL3337506T3 - Kombinacje i ich zastosowania - Google Patents

Kombinacje i ich zastosowania

Info

Publication number: PL3337506T3
Authority: PL; Poland
Prior art keywords: combinations; applications
Prior art date: 2015-08-21

Application number

PL16756997T

Other languages

English (en)

Inventor

Jan Endell

Mark Winderlich

Rainer Boxhammer

Original Assignee

Morphosys Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-08-21

Filing date

2016-08-18

Publication date

2022-01-03

2016-08-18 Application filed by Morphosys Ag filed Critical Morphosys Ag

2022-01-03 Publication of PL3337506T3 publication Critical patent/PL3337506T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Microbiology (AREA)
Mycology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Ultra Sonic Daignosis Equipment (AREA)

PL16756997T 2015-08-21 2016-08-18 Kombinacje i ich zastosowania PL3337506T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP15181925		2015-08-21
PCT/EP2016/069571 WO2017032679A1 (en)	2015-08-21	2016-08-18	Combinations and uses thereof
EP16756997.9A EP3337506B1 (en)	2015-08-21	2016-08-18	Combinations and uses thereof

Publications (1)

Publication Number	Publication Date
PL3337506T3 true PL3337506T3 (pl)	2022-01-03

Family

ID=54010888

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL16756997T PL3337506T3 (pl)	2015-08-21	2016-08-18	Kombinacje i ich zastosowania

Country Status (23)

Country	Link
US (3)	US11224654B2 (pl)
EP (2)	EP3337506B1 (pl)
JP (4)	JP6862422B2 (pl)
KR (2)	KR20180042335A (pl)
CN (2)	CN115054697B (pl)
AU (3)	AU2016311136B2 (pl)
CA (1)	CA2995738A1 (pl)
CY (1)	CY1124706T1 (pl)
DK (1)	DK3337506T3 (pl)
ES (1)	ES2891336T3 (pl)
HR (1)	HRP20211291T1 (pl)
HU (1)	HUE056408T2 (pl)
IL (2)	IL257345B2 (pl)
LT (1)	LT3337506T (pl)
MX (2)	MX392561B (pl)
PL (1)	PL3337506T3 (pl)
PT (1)	PT3337506T (pl)
RS (1)	RS62260B1 (pl)
RU (1)	RU2767063C2 (pl)
SI (1)	SI3337506T1 (pl)
SM (1)	SMT202100541T1 (pl)
WO (1)	WO2017032679A1 (pl)
ZA (1)	ZA201801052B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT3337506T (pt) *	2015-08-21	2021-09-24	Morphosys Ag	Combinações e suas utilizações
HUE054496T2 (hu)	2016-10-28	2021-09-28	Morphosys Ag	CD19 elleni ellenanyag kombinálása BCL-2-gátlóval és alkalmazásuk
KR20200010472A (ko)	2017-05-31	2020-01-30	모르포시스 아게	항-cd19 항체 및 베네토클락스 조합 치료에 대한 치료 패러다임
EP3652206A1 (en)	2017-07-10	2020-05-20	International-Drug-Development-Biotech	Treatment of b cell malignancies using afucosylated pro-apoptotic anti-cd19 antibodies in combination with anti cd20 antibodies or chemotherapeutics
KR20200030337A (ko)	2018-09-12	2020-03-20	주식회사 녹십자랩셀	종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
MX2022005032A (es) *	2019-10-31	2022-07-27	Morphosys Ag	Terapia secuencial anti cumulo de diferenciacion 19 (cd19).
WO2022115762A1 (en) *	2020-11-30	2022-06-02	Incyte Corporation	Combination therapy with an anti-cd19 antibody and parsaclisib
IL313736A (en) *	2021-12-22	2024-08-01	Incyte Corp	Treatment paradigm for CD19 antibody therapy

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4708871A (en)	1983-03-08	1987-11-24	Commonwealth Serum Laboratories Commission	Antigenically active amino acid sequences
US5686072A (en)	1992-06-17	1997-11-11	Board Of Regents, The University Of Texas	Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
SI2223922T1 (sl)	2000-04-25	2016-04-29	Icos Corporation	Inhibitorji humane fosfatidil-inositol 3-kinazne delta izoforme
CN1592645A (zh)	2000-09-18	2005-03-09	拜奥根Idec公司	使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
US7771951B2 (en)	2001-12-03	2010-08-10	Amgen Fremont Inc.	Antibody categorization based on binding characteristics
US20080152649A1 (en) *	2002-03-01	2008-06-26	Xencor, Inc.	Optimized igf-1r antibodies and methods of using the same
US7902338B2 (en)	2003-07-31	2011-03-08	Immunomedics, Inc.	Anti-CD19 antibodies
EP2216342B1 (en)	2003-07-31	2015-04-22	Immunomedics, Inc.	Anti-CD19 antibodies
ES2605792T3 (es)	2004-05-13	2017-03-16	Icos Corporation	Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
BRPI0613279A8 (pt)	2005-06-20	2018-05-02	Medarex Inc	Anticorpo manoclonal isolado, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para preparar um anticorpo anti-cd19, método para inibir o crescimento de células tumorais expressando cd19, e método para depleção de celulas b num indivíduo
ES2426468T3 (es)	2005-12-30	2013-10-23	Merck Patent Gmbh	Anticuerpos anti-CD19 con inmunogenicidad reducida
SI2383297T1 (sl) *	2006-08-14	2013-06-28	Xencor Inc.	Optimizirana antitelesa, ki ciljajo cd19
CN103694349A (zh)	2006-09-08	2014-04-02	米迪缪尼有限公司	人源化抗cd19抗体及其在治疗癌症、移植病和自身免疫病中的应用
LT2176298T (lt)	2007-05-30	2018-04-10	Xencor, Inc.	Būdai ir kompozicijos, skirti cd32b ekspresuojančių ląstelių slopinimui
HUE031533T2 (hu)	2007-10-19	2017-07-28	Seattle Genetics Inc	CD19-kötõszerek valamint alkalmazásuk
AU2010215239A1 (en)	2009-02-23	2011-09-15	Glenmark Pharmaceuticals S.A.	Humanized antibodies that bind to CD19 and their uses
US20120128586A1 (en)	2009-06-24	2012-05-24	The Feinstein Institute For Medical Research	Method for treating chronic lymphocytic leukemia
PT2493503E (pt) *	2009-10-27	2015-11-12	Amgen Res Munich Gmbh	Regime de dosagem para administração de um anticorpo biespecífico cd19xcd3
WO2011147834A1 (en)	2010-05-26	2011-12-01	Roche Glycart Ag	Antibodies against cd19 and uses thereof
EP2409712A1 (en)	2010-07-19	2012-01-25	International-Drug-Development-Biotech	Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en)	2010-07-19	2012-01-25	International-Drug-Development-Biotech	Anti-CD19 antibody having ADCC function with improved glycosylation profile
CN103561759B (zh) *	2010-10-22	2016-10-12	西雅图遗传学公司	以奥里斯他汀(AURISTATIN)为主的抗体药物结合物与PI3K-AKT mTOR路径抑制剂之间的协同作用
EP2524929A1 (en)	2011-05-17	2012-11-21	Sanofi	Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
KR20200060779A (ko)	2011-08-16	2020-06-01	모르포시스 아게	항ｃｄ19 항체 및 퓨린 유사체를 이용한 병용 요법
AU2012296907B2 (en) *	2011-08-16	2017-01-05	Incyte Corporation	Combination therapy with an anti - CD19 antibody and a nitrogen mustard
CA2864305C (en)	2012-03-05	2021-02-16	Gilead Calistoga Llc	Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
SMT201800561T1 (it)	2012-11-01	2018-11-09	Infinity Pharmaceuticals Inc	Trattamento di cancri usando modulatori di isoforme di pi3 chinasi
US9808753B2 (en)	2013-02-15	2017-11-07	3M Innovative Properties Company	System and method for making pleated filter media
EP3157553A4 (en)	2014-06-16	2018-02-28	Xencor, Inc.	Treatment for chronic lymphocytic leukemia (cll)
EP3302550B1 (en)	2015-05-26	2019-08-28	MorphoSys AG	Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
PT3337506T (pt)	2015-08-21	2021-09-24	Morphosys Ag	Combinações e suas utilizações
PL3465214T3 (pl)	2016-05-30	2021-12-20	Morphosys Ag	Sposoby przewidywania korzyści terapeutycznej terapii anty-cd19 u pacjentów
SMT202100317T1 (it)	2016-06-27	2021-07-12	Morphosys Ag	Formulazioni di anticorpi anti-cd19
HUE054496T2 (hu)	2016-10-28	2021-09-28	Morphosys Ag	CD19 elleni ellenanyag kombinálása BCL-2-gátlóval és alkalmazásuk
KR20200010472A (ko)	2017-05-31	2020-01-30	모르포시스 아게	항-cd19 항체 및 베네토클락스 조합 치료에 대한 치료 패러다임
KR20200030337A (ko)	2018-09-12	2020-03-20	주식회사 녹십자랩셀	종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
SG11202111343TA (en)	2019-05-03	2021-11-29	Morphosys Ag	Anti-cd19 therapy in patients having a limited number of nk cells
MX2022005032A (es)	2019-10-31	2022-07-27	Morphosys Ag	Terapia secuencial anti cumulo de diferenciacion 19 (cd19).
IL292213A (en)	2019-10-31	2022-06-01	Morphosys Ag	Combination anti-tumor therapy including anti-cd19 antibody and gamma delta t cells
MX2022005031A (es)	2019-10-31	2022-07-27	Morphosys Ag	Terapia anti cumulo de diferenciacion 19(cd19) en combinacion con lenalidomida para el tratamiento de leucemias o linfomas.
EP4168449A1 (en)	2020-06-22	2023-04-26	MorphoSys AG	Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpa-cd47 innate immune checkpoint
WO2022115762A1 (en)	2020-11-30	2022-06-02	Incyte Corporation	Combination therapy with an anti-cd19 antibody and parsaclisib
US20220184208A1 (en)	2020-12-04	2022-06-16	Morphosys Ag	Anti-cd19 combination therapy
IL313736A (en)	2021-12-22	2024-08-01	Incyte Corp	Treatment paradigm for CD19 antibody therapy

2016
- 2016-08-18 PT PT167569979T patent/PT3337506T/pt unknown
- 2016-08-18 EP EP16756997.9A patent/EP3337506B1/en active Active
- 2016-08-18 RU RU2018107929A patent/RU2767063C2/ru active
- 2016-08-18 WO PCT/EP2016/069571 patent/WO2017032679A1/en not_active Ceased
- 2016-08-18 CN CN202210502807.XA patent/CN115054697B/zh active Active
- 2016-08-18 CN CN201680048061.2A patent/CN107921129B/zh active Active
- 2016-08-18 SI SI201631293T patent/SI3337506T1/sl unknown
- 2016-08-18 SM SM20210541T patent/SMT202100541T1/it unknown
- 2016-08-18 US US15/752,009 patent/US11224654B2/en active Active
- 2016-08-18 LT LTEPPCT/EP2016/069571T patent/LT3337506T/lt unknown
- 2016-08-18 ES ES16756997T patent/ES2891336T3/es active Active
- 2016-08-18 KR KR1020187007728A patent/KR20180042335A/ko not_active Ceased
- 2016-08-18 DK DK16756997.9T patent/DK3337506T3/da active
- 2016-08-18 AU AU2016311136A patent/AU2016311136B2/en active Active
- 2016-08-18 CA CA2995738A patent/CA2995738A1/en active Pending
- 2016-08-18 KR KR1020247011695A patent/KR102786010B1/ko active Active
- 2016-08-18 PL PL16756997T patent/PL3337506T3/pl unknown
- 2016-08-18 IL IL257345A patent/IL257345B2/en unknown
- 2016-08-18 HR HRP20211291TT patent/HRP20211291T1/hr unknown
- 2016-08-18 EP EP21186316.2A patent/EP3954388A1/en active Pending
- 2016-08-18 HU HUE16756997A patent/HUE056408T2/hu unknown
- 2016-08-18 IL IL297057A patent/IL297057B2/en unknown
- 2016-08-18 JP JP2018508728A patent/JP6862422B2/ja active Active
- 2016-08-18 MX MX2018002241A patent/MX392561B/es unknown
- 2016-08-18 RS RS20211009A patent/RS62260B1/sr unknown
2018
- 2018-02-15 ZA ZA2018/01052A patent/ZA201801052B/en unknown
- 2018-02-20 MX MX2022006154A patent/MX2022006154A/es unknown
2021
- 2021-03-31 JP JP2021059383A patent/JP2021113194A/ja active Pending
- 2021-09-17 CY CY20211100817T patent/CY1124706T1/el unknown
- 2021-12-08 US US17/545,274 patent/US12194095B2/en active Active
2022
- 2022-04-28 AU AU2022202800A patent/AU2022202800B2/en active Active
2023
- 2023-03-30 JP JP2023054891A patent/JP2023093495A/ja active Pending
2024
- 2024-04-02 AU AU2024202109A patent/AU2024202109A1/en not_active Abandoned
- 2024-12-02 US US18/965,167 patent/US20250195646A1/en active Pending
2025
- 2025-06-04 JP JP2025093012A patent/JP2025131697A/ja active Pending

Also Published As

Publication number	Publication date
AU2022202800A1 (en)	2022-05-19
IL297057A (en)	2022-12-01
US11224654B2 (en)	2022-01-18
IL257345A (en)	2018-03-29
RU2767063C2 (ru)	2022-03-16
RU2018107929A3 (pl)	2020-01-14
CN115054697A (zh)	2022-09-16
CN115054697B (zh)	2024-06-11
NZ739706A (en)	2025-02-28
EP3337506A1 (en)	2018-06-27
US12194095B2 (en)	2025-01-14
JP2021113194A (ja)	2021-08-05
BR112018003263A2 (pt)	2018-09-25
PT3337506T (pt)	2021-09-24
EP3954388A1 (en)	2022-02-16
CY1124706T1 (el)	2022-07-22
HUE056408T2 (hu)	2022-02-28
JP2023093495A (ja)	2023-07-04
IL257345B (en)	2022-11-01
AU2022202800B2 (en)	2024-01-04
JP6862422B2 (ja)	2021-04-21
IL297057B1 (en)	2025-07-01
US20180228893A1 (en)	2018-08-16
SMT202100541T1 (it)	2021-11-12
HRP20211291T1 (hr)	2021-12-10
MX2018002241A (es)	2018-03-23
AU2016311136B2 (en)	2022-02-17
IL257345B2 (en)	2023-03-01
RU2018107929A (ru)	2019-09-23
KR20240052084A (ko)	2024-04-22
WO2017032679A1 (en)	2017-03-02
ZA201801052B (en)	2021-05-26
MX2022006154A (es)	2022-10-07
IL297057B2 (en)	2025-11-01
JP2025131697A (ja)	2025-09-09
AU2016311136A1 (en)	2018-03-01
CN107921129B (zh)	2022-05-27
CA2995738A1 (en)	2017-03-02
KR20180042335A (ko)	2018-04-25
RS62260B1 (sr)	2021-09-30
DK3337506T3 (da)	2021-09-06
MX392561B (es)	2025-03-24
JP2018523685A (ja)	2018-08-23
EP3337506B1 (en)	2021-07-21
KR102786010B1 (ko)	2025-03-26
CN107921129A (zh)	2018-04-17
US20220088197A1 (en)	2022-03-24
LT3337506T (lt)	2021-10-11
AU2024202109A1 (en)	2024-05-02
SI3337506T1 (sl)	2021-12-31
ES2891336T3 (es)	2022-01-27
HK1247122A1 (zh)	2018-09-21
US20250195646A1 (en)	2025-06-19

Publication	Publication Date	Title
FIC20230014I1 (fi)	2023-03-31	Foslevodopa ja foskarbidopa
IL285286A (en)	2021-09-30	Transposase polypeptides and uses thereof
IL293377A (en)	2022-07-01	Hsd17b13 variants and uses thereof
IL280863A (en)	2021-04-29	Autotaxin inhibitors and uses thereof
PL3265448T3 (pl)	2022-04-25	Proleki riluzolu i ich zastosowanie
PL3373755T3 (pl)	2021-12-27	Część do e-palenia i urządzenie do e-palenia oraz sposób ich wytwarzania
PL3280441T3 (pl)	2022-02-21	Przeciwciała przeciwko sortilinie i sposoby ich stosowania
PL3295951T3 (pl)	2020-10-05	Przeciwciała anty-pvrig i sposoby ich zastosowania
PL4234581T3 (pl)	2026-01-26	Przeciwciała terapeutyczne i ich zastosowania
KR20180084891A (ko)	2018-07-25	구조 조성물 및 방법
PL3157552T3 (pl)	2020-05-18	Polipeptydy syntac i ich zastosowania
PL3148579T3 (pl)	2021-07-19	Przeciwciała anty-gitr i sposoby ich zastosowania
EP3334706A4 (en)	2019-03-13	PILLARARES AND USES THEREOF
MA40933A (fr)	2017-09-19	Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
PL3319612T3 (pl)	2021-12-20	Oksysterole i sposoby ich stosowania
CL2018000700A1 (es)	2019-02-08	Sililfenoxiheterociclos trisustituidos y análogos
DK3209773T3 (da)	2020-06-15	Prolintolerante tripeptidylpeptidaser og anvendelser deraf
DK3128005T3 (da)	2021-06-28	Sirp-alfa-variantkonstruktioner og anvendelser deraf
PL3498292T3 (pl)	2022-02-14	Konstrukty białka uspa2 i ich zastosowania
DK3161139T3 (da)	2020-10-19	Tlr-4-specifikke aptamerer og anvendelser heraf
PL3337506T3 (pl)	2022-01-03	Kombinacje i ich zastosowania
PL3393485T3 (pl)	2026-03-16	Kompozycje probiotyczne i ich zastosowanie
DK3321279T3 (da)	2020-03-09	Exenatidmodificeringsmiddel og anvendelse deraf
DK3365321T3 (da)	2024-01-15	Solabegron-zwitterion og anvendelser deraf
MA49905A (fr)	2021-03-24	Polyesteramines et polyesterquats